Lonza
Lonza Group AG, commonly referred to as Lonza, is a leading global provider of integrated solutions for the pharmaceutical, biotechnology, and specialty ingredients sectors. Headquartered in Switzerland (CH), Lonza operates extensively across Europe, North America, and Asia, delivering innovative products and services that cater to diverse industry needs. Founded in 1897, Lonza has achieved significant milestones, including advancements in cell and gene therapy manufacturing. The company is renowned for its high-quality contract development and manufacturing services (CDMO), as well as its extensive portfolio of active pharmaceutical ingredients (APIs) and custom manufacturing solutions. Lonza's commitment to sustainability and cutting-edge technology positions it as a market leader, consistently recognised for its contributions to the life sciences and healthcare industries.
DitchCarbon Score
How does Lonza's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Furniture Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Lonza's score of 48 is higher than 96% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Lonza's reported carbon emissions
In 2023, Lonza reported total greenhouse gas emissions of approximately 3,190,000 kg CO2e for Scope 1, 2, and 3. Specifically, Scope 1 emissions were about 319,000 kg CO2e, while Scope 2 emissions totalled approximately 202,000 kg CO2e (market-based) and 228,000 kg CO2e (location-based). The company also reported Scope 3 emissions of around 1,876,000 kg CO2e. Lonza has set ambitious climate commitments, aiming for carbon neutrality across all scopes by 2050. In the near term, they plan to reduce Scope 1 and 2 emissions by more than 40% by the end of 2029, with a target to decrease greenhouse gas intensity by 50% per CHF 1 million in sales by 2030, using 2018 as the base year. These initiatives reflect Lonza's commitment to sustainability within the pharmaceuticals and biotechnology sector, aligning with industry standards for climate action.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
Get Started| 2019 | 2020 | 2021 | 2022 | 2023 | |
|---|---|---|---|---|---|
| Scope 1 | 548,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 |
| Scope 2 | 289,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 |
| Scope 3 | - | - | 0,000,000,000 | 0,000,000,000 | 0,000,000,000 |
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Lonza is committed to some reduction initiatives we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
